The major limitations of this feasibility study include the lack of sociodemographic data collection, objective assessment regarding whether these people living with T2D correctly self-titrated their insulin doses or the eventual impact on glycated hemoglobin, time-in-range, and hypoglycemia occurrence. The gene discussed is INS; the disease is Hypoglycemia.